04/12/2024 - General information
She will hold the position for two years and will be responsible for reviewing and supervising the evaluation processes of each call within her field at the agency. Dr. Esther Barreiro, an associate physician in the Pulmonology Service at Hospital del Mar and a researcher at its research institute, has been appointed as the coordinator in the field of medical and health sciences at the Agency for the Management of University and Research Grants (AGAUR).
14/11/2024 - General information
This is a body created to advise the government in this field. Dr. Albert Goday, emeritus section head of the Endocrinology and Nutrition Department at Hospital del Mar, researcher at its research institute, and associate professor of Medicine at UPF, has been appointed president of the Advisory Council on Diabetes in Catalonia. This council's role is to provide guidance to the government on diabetes, and it includes endocrinologists, family doctors, nurses, as well as patients and representatives from patient associations.
19/01/2024 - General information
The Minister of Health officially announced the cardiologist's appointment from Hospital del Mar and researcher at the Hospital del Mar Research Institute last December. Dr. Tizón replaces Dr. Josepa Mauri from Hospital Germans Trias i Pujol, who held this position for the past 8 years.
11/07/2023 - General information
The Tatiana Foundation Prize for Young Researchers, awarded by the Spanish Society of Neurosciences, aims to identify and support the future leaders of Spanish neuroscience research. Valero, coordinator of the Neural Computation Laboratory at the Hospital del Mar Research Institute, has made extraordinary discoveries that have changed the way neuroscientists think about how local neural microcircuits represent spatial information. The award will be presented next September at the XI World Congress of the International Brain Research Organization (IBRO) to be held in Granada and organized by the Spanish Society of Neurosciences.
15/12/2022 - General information
The study, led by Dr. Xavier Nogués, has received one of the two biomedical research grants awarded by this organization, with a total endowment of 650,000 euros. The award ceremony took place in Madrid on December 14. A project to identify the factors that affect the risk of developing a state of fragility, headed by Dr. Xavier Nogués, director of the Clinical Translational Research Program at the Hospital del Mar Medical Research Institute and head of the Internal Medicine Department at the Hospital del Mar, has received one of the two grants for biomedical research awarded by the Francisco Soria Melguizo Foundation. These grants total 650,000 euros and were awarded on December 14 at a ceremony held at the Royal National Academy of Pharmacy in Madrid.
30/09/2022 - General information
An international collaborative study involving the Hospital del Mar Medical Research Institute and the Hospital del Mar has analyzed data from over 200,000 stroke patients and more than two million control individuals from five different ancestries. This study has associated 89 genes, of which 69 were previously unknown, with stroke and its subtypes. The research provides crucial insights to guide future biological investigations into the processes leading to this condition. Additionally, it reveals that some of these genes could potentially serve as targets for drugs to prevent or treat this disease. It also offers genetic prediction tools, improved and validated for the first time in non-European populations, to guide the development of new drugs.
30/03/2022 - General information
A study by the Neuroimmunology Research Group at the Hospital del Mar Medical Research Institute (IMIM) has validated a possible marker that could improve the efficiency of one of the main multiple sclerosis treatments. The marker is a specific type of immune system cell, known as NK (Natural Killer) cells, which express a specific receptor on their surface, NKG2C. Currently, patients with multiple sclerosis are treated with anti-CD20 monoclonal antibodies, which are designed to eliminate the B-lymphocyte population in peripheral blood and thus control disease activity. These drugs are scheduled to be administered once every six months, although it is unclear whether this time period is appropriate for all patients. Several studies indicate that, depending on the drug given, it takes between six months and a year and a half for the levels of the B-lymphocyte population to recover.
11/02/2022 - General information
The head of the Infectious Diseases Department at Hospital del Mar and coordinator of the Infectious Pathology and Antimicrobial Research Group at the Hospital del Mar Medical Research Institute, was appointed to this body, which is part of the European Medicines Agency (EMA), last month. The European Medicines Agency (EMA) has selected Dr. Juan Pablo Horcajada, head of the Infectious Diseases Department at Hospital del Mar and coordinator of the Infectious Pathology and Antimicrobial Research Group at the Hospital del Mar Medical Research Institute (IMIM) as a member of its Scientific Advisory Group on Infectious Diseases. This is a body comprising experts in this field from several European countries, chosen by the agency after a selection process, following a proposal from the national medicines agencies.
01/12/2021 - General information
The board of the Spanish Society of Pneumology and Thoracic Surgery has decided that the Hospital del Mar pneumologist and researcher at the Hospital del Mar Medical Research Institute will head up the committee responsible for managing and organising the society's policy documents. The Spanish Society of Pneumology and Thoracic Surgery (SEPAR), has appointed Dr. Esther Barreiro, a consultant in the Pneumology Department at Hospital del Mar and coordinator of the Muscle Wasting and Cachexia in Chronic Respiratory Diseases and Lung Cancer Research Group at the Hospital del Mar Medical Research Institute (IMIM), as coordinator of the SEPAR committee responsible for managing the regulations and recommendations that will be issued by the society. The appointment was made at the first meeting of the new SEPAR governing board.
Més informació "Dr. Esther Barreiro, coordinator of SEPAR regulations and recommendations"
16/11/2021 - General information
Researchers from the Hospital del Mar Medical Research Institute and CIBERES detect an increase in oxidative stress in these patients that may favour tumour development. Reduced levels of the potent antioxidant glutathione may be used as a new early biomarker of cancer in people with chronic respiratory disease. The risk of developing lung cancer increases in patients with COPD (Chronic Obstructive Pulmonary Disease), so understanding the cellular mechanism involved in tumour progression is key. Indeed, researchers from the Hospital del Mar Medical Research Institute (IMIM-Hospital del Mar) and the CIBER on Respiratory Diseases (CIBERES) have just published a study in the journal Biomedicines that identifies the role of systemic oxidative and antioxidant markers, which are differentially expressed in these patients with chronic respiratory diseases, and are therefore involved in the development of lung cancer.
Més informació "Lung cancer patients with COPD have worse disease progression"
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
